BRISBANE, Australia 19 July 2007 Peplin Limited (ASX:PEP) today announced positive preliminary results of PEP005-006 its 220 patient US-based phase IIb actinic (solar) keratosis (AK) clinical study. AKs are common precancerous skin lesions, caused by sun exposure, a portion of which develop into skin cancer.
